Can private equity really scale chicken sausage into America’s next protein craze?

Private equity firms TowerBrook Capital Partners and Prelude Growth Partners are betting that chicken sausage is ready to move from a niche health product into the mainstream of American protein consumption. Their strategic investment in Chicago-based Amylu Foods — known for its all-natural, antibiotic-free chicken sausages, meatballs, and burgers — highlights how investors see opportunity in fresh poultry proteins as consumers shift away from red meat and lose appetite for heavily processed plant-based substitutes.

Amylu Foods, founded on the principle of clean-label eating, has built its reputation by stripping out preservatives and additives. Its products avoid nitrates and antibiotics while delivering convenience in formats like pre-cooked sausages and bite-sized meatballs. For TowerBrook, the attraction lies in Amylu’s hybrid model: it sells under its own branded portfolio while also producing private-label items for major grocers. This dual presence allows it to tap two fast-growing revenue streams — branded natural foods and retail-controlled house brands.

Why are private equity investors turning to poultry-based protein brands instead of chasing plant-based hype?

Over the past decade, plant-based meat alternatives captured investor imagination with promises of disrupting traditional protein consumption. But while early entrants drew headlines and capital, sales growth has flattened as consumers questioned flavor, price, and processing levels. Poultry has emerged as a stronger contender for shoppers seeking a healthier middle ground.

Chicken is widely perceived as leaner and more sustainable than beef or pork, while still being familiar to consumers. Amylu Foods has leaned heavily into this narrative, positioning its products as indulgent yet responsible — offering the flavor of sausage or burgers without the guilt of excess fat or synthetic preservatives.

Private equity investors now view poultry protein brands as steadier bets, combining the growth profile of “better-for-you” eating trends with the reassurance of mainstream appeal. According to analysts, natural chicken products have proven sticky in consumer baskets, even during periods of food inflation, giving them resilience plant-based alternatives have struggled to maintain.

What challenges does Amylu Foods face as it tries to scale into a national protein player?

Scaling a mid-sized fresh protein brand is no small task. Distribution is often the biggest bottleneck. Gaining shelf space in national chains requires marketing clout, reliable logistics, and consistent production capacity. TowerBrook’s capital injection is expected to help Amylu build out manufacturing infrastructure, expand supply chain resilience, and negotiate broader distribution agreements.

But headwinds remain. Poultry costs are notoriously volatile, tied to global feed prices and disease risks such as avian flu outbreaks. Competitors like Tyson Foods and Hormel already dominate the protein aisle, leaving limited space for challengers. To break through, Amylu must use its clean-label differentiation as a wedge to win over both retailers and end consumers. Price competitiveness will also be key; while niche shoppers are willing to pay premiums for natural foods, scaling nationally requires affordability.

Institutional investors note that brand storytelling around health, sustainability, and convenience will need to keep pace with operational expansion. Without strong marketing, even the most innovative protein products can be drowned out in a crowded grocery aisle.

How is institutional sentiment shaping expectations for Amylu Foods after the TowerBrook investment?

The reaction among institutional observers has been cautiously optimistic. Poultry proteins are considered relatively defensive investments compared with red meat, particularly during inflationary cycles. By partnering with private equity, Amylu Foods is expected to secure capital discipline, supply chain upgrades, and strategic guidance on scaling.

Investors also recognize the value of Amylu’s private-label supply, which provides stable volume contracts and diversifies risk beyond branded product sales. This positions the company to weather fluctuations in consumer demand more effectively than single-channel competitors.

Still, there is recognition that execution will determine outcomes. Investors view Amylu’s potential public market exit or acquisition by a larger CPG player as plausible scenarios if it can demonstrate consistent growth. For now, the sentiment reflects a “wait and watch” attitude: optimism about poultry’s category momentum tempered by awareness of execution risks.

Could chicken sausage become the next national protein craze in the U.S.?

Whether chicken sausages can capture the imagination of mainstream America in the way plant-based once did remains to be seen. Advocates argue that poultry’s balance of familiarity, health appeal, and sustainability credentials make it a strong candidate for category expansion. Retailers and foodservice chains are increasingly allocating shelf space to “better-for-you” proteins, suggesting an environment conducive to growth.

If Amylu Foods leverages TowerBrook’s investment to expand distribution, maintain product quality, and compete on price, chicken sausages may indeed achieve the kind of visibility once reserved for plant-based disruptors. But the race is far from guaranteed. The protein wars are intensifying, and consumer loyalty can shift quickly in response to trends, pricing, and marketing.

For now, what is clear is that private equity sees enough in Amylu’s growth story to double down on poultry’s potential. And if chicken sausage does become America’s next protein craze, TowerBrook’s bet could look very prescient indeed.